NCT03942666 is a Phase 1 clinical trial of Treatment A in Asthma, sponsored by Chiesi Farmaceutici S.p.A..

Who is sponsoring NCT03942666?

NCT03942666 is sponsored by Chiesi Farmaceutici S.p.A..

What drugs are being tested in NCT03942666?

Interventions in NCT03942666: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F.

Is NCT03942666 still recruiting?

NCT03942666 is currently completed. Last updated 22 July 2020.

Last reviewed 2020-07-22 · How we verify

NCT03942666

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Completed Phase 1 Last updated 22 July 2020

What this trial tests

Phase 1 trial testing Treatment A in Asthma in 30 participants. Completed in 22 November 2019.

Timeline

10 May 2019

Primary endpoint
22 November 2019

22 November 2019

Quick facts

Lead sponsor	Chiesi Farmaceutici S.p.A.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	other
Enrollment	30
Start date	10 May 2019
Primary completion	22 November 2019
Estimated completion	22 November 2019
Sites	1 location across Belgium

Drugs / interventions tested

Treatment A (treatment-a) — full drug profile →
Treatment B (treatment-b) — full drug profile →
Treatment C (treatment-c) — full drug profile →
Treatment D (treatment-d) — full drug profile →
Treatment E
Treatment F — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Chiesi Farmaceutici S.p.A. — full company profile →

Who can join

Adults 18 to 60, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this clinical pharmacology study is to evaluate the CHF 6532 linearity after single oral administrations of four doses of a tablet formulation and to evaluate the pharmacokinetic (PK) at steady state following the repeated open label b.i.d. administration at one dose.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Treatment A

Trials testing the same drug.

NCT07229404 — A Study to Investigate Relative Bioavailability, Safety and Tolerability of Single- and Multiple-doses of Elinzanetant i · Phase 1 · completed
NCT06661694 — A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults · Phase 1 · withdrawn
NCT06693518 — A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigat · Phase 1 · completed
NCT05868356 — A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib · Phase 1 · completed
NCT07214922 — Relative Bioavailability of Evobrutinib Tablet Batches · Phase 1 · completed

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Chiesi Farmaceutici S.p.A. trials

Trials by the same sponsor.

NCT07516951 — A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis · Phase 2 · not yet recruiting
NCT07301736 — Therapeutic Equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in Subjects With Mild to Moderate Asthma · Phase 2 · recruiting
NCT07163182 — Evaluation of Safety, Side Effects and How the Drug CHF6467 Administered Via Intranasal Route is Absorbed, Modified and · Phase 1 · recruiting
NCT06900816 — A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate C · Phase 2 · completed
NCT06892756 — Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03942666 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Chiesi Farmaceutici S.p.A.
Last refreshed: 22 July 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03942666.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing